Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 75.42% is in line with its 5-year average of 79.39%, around the middle of its 5-year range (71.88%–82.81%).
1.56% below its 12-month average of 76.62%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 75.81%.
GROSS MARGIN
75.42%
GROSS MARGIN AVG TTM
76.62%
GROSS MARGIN AVG 3Y
78.07%
GROSS MARGIN AVG 5Y
79.39%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.56%
CURRENT VS 3Y AVG
-3.40%
CURRENT VS 5Y AVG
-5.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
39.94%
median of 722 covered companies
CURRENT VS SECTOR MEDIAN
+88.83%
vs the sector median at left
Harmony Biosciences Holdings, Inc.
Market Cap
$2.30B
Gross Margin
75.42%
TTM Avg
76.62%
3Y Avg
78.07%
5Y Avg
79.39%
Market Cap
$2.27B
Gross Margin
17.98%
TTM Avg
29.88%
3Y Avg
47.29%
5Y Avg
57.26%
Market Cap
$2.35B
Gross Margin
92.48%
TTM Avg
74.82%
3Y Avg
78.80%
5Y Avg
76.59%
Market Cap
$2.37B
Gross Margin
77.55%
TTM Avg
-114.38%
3Y Avg
-188.02%
5Y Avg
-219.43%
Market Cap
$2.38B
Gross Margin
64.71%
TTM Avg
54.44%
3Y Avg
41.55%
5Y Avg
20.41%
Market Cap
$2.39B
Gross Margin
18.57%
TTM Avg
22.55%
3Y Avg
18.71%
5Y Avg
13.63%
Market Cap
$2.41B
Gross Margin
56.20%
TTM Avg
28.10%
3Y Avg
28.10%
5Y Avg
28.10%
Market Cap
$2.42B
Gross Margin
-61.96%
TTM Avg
-19.42%
3Y Avg
-14.39%
5Y Avg
23.74%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | $2.30B | 75.42% | 76.62% | 78.07% | 79.39% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.27B | 17.98% | 29.88% | 47.29% | 57.26% |
| Liquidia Corporation (LQDA)vs › | $2.35B | 92.48% | 74.82% | 78.80% | 76.59% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.37B | 77.55% | -114.38% | -188.02% | -219.43% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.38B | 64.71% | 54.44% | 41.55% | 20.41% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.39B | 18.57% | 22.55% | 18.71% | 13.63% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.41B | 56.20% | 28.10% | 28.10% | 28.10% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.42B | -61.96% | -19.42% | -14.39% | 23.74% |
| Disc Medicine, Inc. (IRON)vs › | $2.44B | 0.00% | 0.00% | 0.00% | 0.00% |
| Pharvaris N.V. (PHVS)vs › | $2.14B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
75.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 75.81% |
| 2026-03-31 | 79.33% |
| 2025-12-31 | 71.88% |
| 2025-09-30 | 75.09% |
| 2025-06-30 | 80.97% |
| 2025-03-31 | 82.68% |
| 2024-12-31 | 72.97% |
| 2024-09-30 | 77.01% |
| 2024-06-30 | 81.40% |
| 2024-03-31 | 82.22% |
| 2023-12-31 | 74.38% |
| 2023-09-30 | 79.85% |
| 2023-06-30 | 81.37% |
| 2023-03-31 | 82.56% |
| 2022-12-31 | 79.05% |
| 2022-09-30 | 80.41% |
| 2022-06-30 | 82.32% |
| 2022-03-31 | 82.75% |
| 2021-12-31 | 80.47% |
| 2021-09-30 | 81.91% |
| 2021-06-30 | 82.81% |
| 2021-03-31 | 82.56% |
| 2020-12-31 | 82.38% |
| 2020-09-30 | 82.70% |
| 2020-06-30 | 83.01% |
| 2020-03-31 | 82.49% |
| 2019-12-31 | 73.69% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
